Unified Investment Management Decreases Stock Position in Bristol Myers Squibb Company (NYSE:BMY)

Unified Investment Management lessened its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 66.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,111 shares of the biopharmaceutical company's stock after selling 16,274 shares during the period. Unified Investment Management's holdings in Bristol Myers Squibb were worth $495,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $1,989,525,000. Ameriprise Financial Inc. lifted its position in shares of Bristol Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after acquiring an additional 12,011,983 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Bristol Myers Squibb by 701.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 12,470,106 shares of the biopharmaceutical company's stock worth $705,309,000 after acquiring an additional 10,913,708 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Bristol Myers Squibb by 3,880.0% during the 4th quarter. Wellington Management Group LLP now owns 5,977,505 shares of the biopharmaceutical company's stock valued at $338,088,000 after acquiring an additional 5,827,317 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $257,618,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald reiterated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Argus upgraded shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. UBS Group lowered their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Finally, William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Price Performance

NYSE BMY traded up $0.01 on Thursday, hitting $47.02. The company had a trading volume of 7,016,940 shares, compared to its average volume of 12,867,601. The company's fifty day moving average price is $47.78 and its 200-day moving average price is $53.75. Bristol Myers Squibb Company has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market capitalization of $95.68 billion, a PE ratio of 17.58, a PEG ratio of 1.41 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The firm had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same period in the previous year, the business earned ($4.40) earnings per share. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. As a group, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.27%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.